Bellerophon Therapeutics, Inc. (BLPH) 10-K Annual Report March 2021

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2020	Mar. 08, 2021	Jun. 30, 2020
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2020
Entity File Number	001-36845
Entity Registrant Name	Bellerophon Therapeutics, Inc.
Entity Tax Identification Number	47-3116175
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	184 Liberty Corner Road
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Warren
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07059
City Area Code	908
Local Phone Number	574-4770
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	BLPH
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Central Index Key	0001600132
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Public Float			$ 86.9
Entity Common Stock, Shares Outstanding		9,491,111

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1600132/000155837021002768/blph-20201231x10k.htm

View differences made from one year to another to evaluate Bellerophon Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Bellerophon Therapeutics, Inc..

Continue

Assess how Bellerophon Therapeutics, Inc.'s management team is paid from their Annual Proxy

Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Other

Filter Subcategory:

All

Expense

Product

Dividend

Other

Inside Bellerophon Therapeutics, Inc.'s 10-K Annual Report:

Financial - Expense Highlight
Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and are recognized as research and development expense as the related goods are delivered or the related services are performed.

Financial - Shares Highlight
We may continue to pursue potential sources of funding, including equity financing and previously were able to obtain funding from equity offerings and sale of tax attributes, including: On June 25, 2018, we filed a shelf registration statement on Form S-3 with the SEC, which became effective on July 6, 2018.
Financial - Shares Highlight
On February 5, 2020, we filed a certificate of amendment to our amended and restated Certificate of Incorporation to effect a 1 - for- 15 reverse stock split of our outstanding shares of common stock, which became effective on February 7, 2020.
Revenue - Product Highlight
On May 22, 2020, we completed the sale of 3,365,384 shares of our common stock in a public offering and concurrent registered direct offering including a full exercise of an option to purchase additional shares at a price of $13.00 per share, resulting in net proceeds of approximately $40.6 million, after deducting agent fees of $2.9 million and offering costs of $0.3 million.
Revenue - Product Highlight
The proceeds from such sales are recorded as income tax benefit when sales occur or proceeds are received.
Revenue - Product
The proceeds from such sales...Read more
Financial - Expense
This increase was primarily due...Read more
Other - Other
For example, if the FDA...Read more
Other - Other
In May 2020, we sold...Read more
Revenue - Product
On January 25, 2019, we...Read more
Revenue - Product
On April 1, 2020, we...Read more
Revenue - Product
The trial showed a statistically...Read more
Financial - Expense
Our primary uses of capital...Read more
Financial - Dividend
Following the internal reorganization, in...Read more
Revenue - Product
In July 2020, we entered...Read more
Financial - Expense
INOpulse engineering expenses for the...Read more
Financial - Expense
General and administrative expenses for...Read more
Financial - Expense
Upfront and milestone payments made...Read more
Other - Other
The data showed INOpulse provided...Read more
Financial - Expense
Total research and development expenses...Read more
Other - Other
The improvements in MVPA was...Read more
Financial - Expense
Total operating expenses for the...Read more
Other - Other
We have sold $21.2 million...Read more
Revenue - Product
In April 2018, we expanded...Read more
Financial - Expense
Research and development expenses primarily...Read more
Other - Other
The new standard became effective...Read more
Financial - Expense
Research and development expenses consist...Read more
Other - Other
The results from this trial...Read more
Other - Other
The financial terms of these...Read more
Other - Other
We believe that our second...Read more
Financial - Expense
Total research and development expenses...Read more
Other - Other
The amendment is effective for...Read more
Financial - Expense
Subject to the availability of...Read more
Other - Other
Cohort 2 of iNO-PF suggested...Read more
Other - Other
The data suggested that inhaled...Read more
Other - Other
The data suggested that the...Read more
Other - Other
Various PAH treatments have been...Read more
Other - Other
The results suggested directional improvements...Read more
Other - Other
The trial results showed 6MWD...Read more
Revenue - Product
If we raise additional funds...Read more
Financial - Expense
The duration, costs and timing...Read more
Other - Other
Although we do not expect...Read more
Other - Other
We will determine which programs...Read more
Financial - Expense
The increase was primarily due...Read more
Financial - Shares
Such shares were sold pursuant...Read more
Financial - Shares
Such shares were sold pursuant...Read more
Other - Other
While our significant accounting policies...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Bellerophon Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 4.5: Instruments Defining The Rights Of Security Holders, Including Indentures

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32: Section 1350 Certification

Ticker: BLPH
CIK: 1600132
Form Type: 10-K Annual Report
Accession Number: 0001558370-21-002768
Submitted to the SEC: Thu Mar 11 2021 8:31:34 AM EST
Accepted by the SEC: Thu Mar 11 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/blph/0001558370-21-002768.htm

Bellerophon Therapeutics, Inc. (BLPH) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

SEC Filings

BLPH Valuations

BLPH Annual Reports

BLPH Quarterly Reports

BLPH Corporate News